,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,A1CF,"ACF, ACF64, ACF65, APOBEC1CF, ASP",ENSG00000148584,APOBEC1 complementation factor,10,50799409-50885675,Predicted intracellular proteins,Evidence at protein level,"HPA037779, HPA044079",Enhanced,,Supported,Nucleoplasm,,Tissue enriched,Tissue enhanced,,liver: 76.0;small intestine: 29.8,duodenum: 23.5,Group enriched,18.0,CACO-2: 19.3;Hep G2: 41.7
1,AADAT,"KAT2, KATII, KYAT2",ENSG00000109576,Aminoadipate aminotransferase,4,170060222-170091699,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037502,Enhanced,,Approved,Vesicles<br>Plasma membrane,Colorectal cancer:5.59e-4 (favourable),Expressed in all,Tissue enhanced,,liver: 34.7,prostate: 23.4,Mixed,,
2,ABAT,GABAT,ENSG00000183044,4-aminobutyrate aminotransferase,16,8674565-8784575,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041528, HPA041690",Enhanced,Supported,Supported,Mitochondria,"Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 164.5;kidney: 135.3;liver: 175.2,thyroid gland: 47.5,Cell line enhanced,,Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1
3,ABCA6,EST155051,ENSG00000154262,ATP binding cassette subfamily A member 6,17,69078702-69141888,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA064878, HPA067180",,,Approved,Nucleoplasm,Liver cancer:3.29e-4 (favourable),Tissue enriched,Tissue enhanced,,liver: 41.4,ovary: 37.4,Cell line enhanced,,ASC diff: 28.1;ASC TERT1: 41.4;HSkMC: 18.8;HUVEC TERT2: 47.8
4,ABCC6,"ARA, EST349056, MLP1, MRP6, PXE, URG7",ENSG00000091262,ATP binding cassette subfamily C member 6,16,16148928-16223522,"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA038105,,,Supported,Plasma membrane,Liver cancer:3.82e-4 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 16.9;liver: 23.4,duodenum: 13.0,Cell line enriched,6.0,Hep G2: 45.5
5,ACOX2,"BRCACOX, BRCOX, THCCox",ENSG00000168306,Acyl-CoA oxidase 2,3,58505136-58537319,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038280, HPA064845",Enhanced,,Supported,Vesicles<br>Cytosol,,Tissue enhanced,Tissue enhanced,,liver: 87.9,kidney: 42.5,Cell line enhanced,,ASC diff: 10.4;ASC TERT1: 17.4;fHDF/TERT166: 6.6;Hep G2: 7.0;HSkMC: 11.8
6,ACSM3,"SA, SAH",ENSG00000005187,Acyl-CoA synthetase medium-chain family member 3,16,20610243-20797581,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA041013,Uncertain,,,,"Renal cancer:9.88e-6 (favourable), Ovarian cancer:1.97e-4 (favourable)",Mixed,Tissue enhanced,,liver: 93.2,kidney: 90.8,Group enriched,12.0,HEL: 85.7;HMC-1: 339.4;K-562: 258.6
7,ADH1C,ADH3,ENSG00000248144,"Alcohol dehydrogenase 1C (class I), gamma polypeptide",4,99336492-99353027,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA047814, HPA060902",Supported,,Supported,Plasma membrane<br>Cytosol,"Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable)",Tissue enriched,Tissue enhanced,,duodenum: 508.1;liver: 888.0;stomach: 477.4,colon: 276.3,Cell line enhanced,,ASC TERT1: 2.5;HSkMC: 7.7
8,ADRA1A,"ADRA1C, ADRA1L1",ENSG00000120907,Adrenoceptor alpha 1A,8,26748150-26867273,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA029678, HPA029679",Approved,,,,,Tissue enhanced,Tissue enhanced,,adipose tissue: 22.6;liver: 31.6;prostate: 20.8,seminal vesicle: 19.1,Not detected,,
9,AFP,"FETA, HPAFP",ENSG00000081051,Alpha fetoprotein,4,73431138-73456174,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA010607, HPA023600, CAB024283, CAB025339",Approved,,Uncertain,Cytosol,,Group enriched,Tissue enhanced,,liver: 1.9,breast: 0.5,Cell line enriched,158.0,Hep G2: 1466.5
10,AGMO,"FLJ16237, TMEM195",ENSG00000187546,Alkylglycerol monooxygenase,7,15200318-15562015,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057900,,,Uncertain,Vesicles,,Tissue enriched,Tissue enhanced,,liver: 63.7,epididymis: 17.6,Cell line enhanced,,Karpas-707: 5.6;SCLC-21H: 3.8;WM-115: 15.2
11,AGT,SERPINA8,ENSG00000135744,Angiotensinogen,1,230702523-230714297,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001557, CAB025798",Supported,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 226.5;liver: 649.6,gallbladder: 133.7,Cell line enhanced,,CACO-2: 60.4;Hep G2: 401.1;THP-1: 150.6
12,ALDH1L1,"10-fTHF, FTHFD",ENSG00000144908,Aldehyde dehydrogenase 1 family member L1,3,126103562-126197994,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036900, HPA050139",Enhanced,Supported,Supported,Cytosol,Renal cancer:2.42e-8 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 121.2;liver: 190.4,adipose tissue: 80.9,Cell line enhanced,,Hep G2: 54.9;Karpas-707: 57.9;RT4: 174.8
13,ALDH4A1,"ALDH4, P5CDh",ENSG00000159423,Aldehyde dehydrogenase 4 family member A1,1,18871430-18902781,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004645, HPA006401",Enhanced,,,,Cervical cancer:5.06e-4 (favourable),Expressed in all,Tissue enhanced,,kidney: 185.7;liver: 108.1,adipose tissue: 63.8,Expressed in all,,
14,ANGPTL6,"AGF, ARP5",ENSG00000130812,Angiopoietin like 6,19,10092338-10102796,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,liver: 11.0,lymph node: 3.9,Cell line enriched,9.0,HMC-1: 51.7
15,APOA1,,ENSG00000118137,Apolipoprotein A1,11,116835751-116837950,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016778, HPA046715",Supported,,Approved,Vesicles<br>Cytosol,"Renal cancer:1.67e-8 (unfavourable), Liver cancer:5.05e-4 (favourable)",Tissue enriched,Tissue enhanced,,liver: 8458.6;small intestine: 4128.6,duodenum: 1609.4,Cell line enriched,15.0,Hep G2: 1951.8
16,AQP9,"HsT17287, SSC1",ENSG00000103569,Aquaporin 9,15,58138169-58185911,Predicted membrane proteins,Evidence at protein level,"HPA074762, CAB075684",Enhanced,,,,Renal cancer:5.72e-11 (unfavourable),Tissue enriched,Tissue enhanced,,appendix: 102.4;liver: 353.0,epididymis: 50.3,Cell line enriched,37.0,U-87 MG: 27.9
17,ARG1,,ENSG00000118520,Arginase 1,6,131573144-131584332,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA003595, CAB009434, HPA024006, CAB056159",Enhanced,,,,,Tissue enriched,Tissue enhanced,,bone marrow: 171.2;liver: 566.2,skin: 78.2,Not detected,,
18,ARSE,"CDPX, CDPX1",ENSG00000157399,Arylsulfatase E (chondrodysplasia punctata 1),X,2934632-2968310,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA060518, HPA070651",Approved,,Supported,Golgi apparatus,Colorectal cancer:8.95e-4 (favourable),Mixed,Tissue enhanced,,kidney: 41.3;liver: 49.3,pancreas: 23.9,Cell line enhanced,,A549: 65.1;CACO-2: 37.1;Hep G2: 46.2;NTERA-2: 32.8
19,ART4,"CD297, DO, DOK1",ENSG00000111339,ADP-ribosyltransferase 4 (Dombrock blood group),12,14825569-14843495,"Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA075664,,,Approved,Rods & Rings,,Tissue enhanced,Tissue enhanced,,liver: 27.2;spleen: 26.9,gallbladder: 15.1,Cell line enhanced,,AN3-CA: 5.6;HEL: 10.9;Hep G2: 4.9;HUVEC TERT2: 22.5
20,ASPDH,,ENSG00000204653,Aspartate dehydrogenase domain containing,19,50511600-50514690,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042631, HPA042654",Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 17.9;kidney: 27.9;liver: 34.6,duodenum: 6.9,Cell line enhanced,,HEK93: 12.4;MOLT-4: 13.3;SH-SY5Y: 9.8
21,ASPG,C14orf76,ENSG00000166183,Asparaginase,14,104085679-104115581,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA069761,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,liver: 29.5,esophagus: 13.9,Not detected,,
22,ASS1,"ASS, CTLN1",ENSG00000130707,Argininosuccinate synthase 1,9,130444929-130501274,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020896, HPA020934",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:8.14e-9 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 1259.9;liver: 1027.3,fallopian tube: 261.5,Cell line enhanced,,BJ hTERT+: 709.0;HaCaT: 734.6;RPMI-8226: 956.8;THP-1: 690.3
23,AZGP1,"ZA2G, ZAG",ENSG00000160862,"Alpha-2-glycoprotein 1, zinc-binding",7,99966720-99976157,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA012582, CAB016087, CAB032276",Enhanced,,,,"Renal cancer:1.53e-4 (favourable), Liver cancer:2.90e-4 (favourable)",Group enriched,Tissue enhanced,,breast: 1201.5;liver: 1272.1;prostate: 1490.2;salivary gland: 1423.5,kidney: 294.4,Cell line enhanced,,Hep G2: 33.7;RPMI-8226: 79.5;T-47d: 35.0
24,BCHE,"CHE1, CHE2, E1",ENSG00000114200,Butyrylcholinesterase,3,165772904-165837472,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA001560,Approved,,,,Head and neck cancer:1.06e-4 (unfavourable),Group enriched,Tissue enhanced,,liver: 265.5,endometrium: 67.7,Cell line enriched,7.0,Karpas-707: 542.1
25,BCO2,"B-DIOX-II, BCDO2, FLJ34464",ENSG00000197580,Beta-carotene oxygenase 2,11,112175467-112224699,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039825, HPA040695",Uncertain,,,,,Mixed,Tissue enhanced,,heart muscle: 21.7;liver: 25.7,adrenal gland: 16.9,Cell line enhanced,,CAPAN-2: 5.2;HHSteC: 10.3
26,C1orf168,"FLJ43208, RP4-758N20.2",ENSG00000187889,Chromosome 1 open reading frame 168,1,56718804-56819696,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,fallopian tube: 21.4;liver: 8.6,"cervix, uterine: 5.0",Cell line enriched,22.0,T-47d: 4.8
27,C2,,ENSG00000166278,Complement C2,6,31897785-31945672,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB016775,Supported,,,,Renal cancer:2.64e-7 (unfavourable),Tissue enriched,Tissue enhanced,,liver: 86.3;lung: 42.6,placenta: 21.9,Group enriched,5.0,Hep G2: 30.0;Karpas-707: 94.7
28,C2orf72,LOC257407,ENSG00000204128,Chromosome 2 open reading frame 72,2,231037490-231049719,Predicted intracellular proteins,Evidence at protein level,HPA044962,Uncertain,,Approved,Nucleus<br>Plasma membrane,"Renal cancer:4.74e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.8;colon: 2.9;liver: 4.7,stomach: 1.3,Cell line enhanced,,BEWO: 8.2;CACO-2: 1.7;EFO-21: 2.9
29,C4A,"C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG",ENSG00000244731,Complement C4A (Rodgers blood group),6,31982024-32002681,"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB009811, CAB032603, HPA046356, HPA048287, HPA050103",Approved,,,,,Tissue enhanced,Tissue enhanced,,liver: 46.1,thyroid gland: 28.2,Group enriched,8.0,HDLM-2: 49.4;HSkMC: 51.4;U-266/70: 12.8;U-266/84: 23.9
30,C4B,"C4B1, C4B3, C4F, CH, CO4, CPAMD3",ENSG00000224389,Complement C4B (Chido blood group),6,32014762-32035418,"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA046356, HPA048287, HPA050103",Approved,,,,,Tissue enhanced,Tissue enhanced,,adrenal gland: 59.4;liver: 65.5,"fallopian tube,kidney: 18.3",Cell line enriched,5.0,Karpas-707: 92.1
31,CA5A,"CA5, CAV, CAVA",ENSG00000174990,Carbonic anhydrase 5A,16,87881546-87936529,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,liver: 1.3,bone marrow: 0.8,Cell line enhanced,,Hep G2: 1.4
32,CBS,HIP4,ENSG00000160200,Cystathionine-beta-synthase,21,43053191-43076943,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA001223,Supported,,Approved,Nucleoli<br>Vesicles,,Mixed,Tissue enhanced,,liver: 56.6;ovary: 31.1,cerebral cortex: 19.8,Cell line enhanced,,HAP1: 171.2;HHSteC: 181.6
33,CBSL,,ENSG00000274276,Cystathionine-beta-synthase like,21,6444869-6468040,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA001223,Supported,,Approved,Nucleoli<br>Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 45.9;liver: 27.3,thyroid gland: 22.2,Cell line enhanced,,AN3-CA: 123.4;NTERA-2: 245.4;SH-SY5Y: 82.5
34,CDO1,,ENSG00000129596,Cysteine dioxygenase type 1,5,115804733-115816954,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036573, HPA057503",Enhanced,,Uncertain,Nucleoplasm,Liver cancer:1.91e-5 (favourable),Group enriched,Tissue enhanced,,epididymis: 137.5;liver: 209.9,adipose tissue: 104.0,Cell line enhanced,,AF22: 38.7;ASC diff: 32.4;HAP1: 14.4;NTERA-2: 14.5
35,CFH,"ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS",ENSG00000000971,Complement factor H,1,196651878-196747504,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB016385, CAB016769, HPA038922, HPA049176, HPA053326",Supported,,Approved,Vesicles,Renal cancer:1.92e-6 (unfavourable),Tissue enriched,Tissue enhanced,,liver: 839.5,gallbladder: 205.3,Cell line enhanced,,HHSteC: 100.0;RT4: 176.9
36,CFI,"C3b-INA, FI, IF, KAF",ENSG00000205403,Complement factor I,4,109740694-109802179,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA001143, CAB016777, HPA024061",Supported,,,,Urothelial cancer:6.06e-4 (unfavourable),Expressed in all,Tissue enhanced,,liver: 524.7,kidney: 221.8,Cell line enhanced,,CAPAN-2: 112.1;Hep G2: 117.9;HSkMC: 48.7;RPTEC TERT1: 139.4
37,CH507-9B2.2,,ENSG00000279493,,21,5011799-5017145,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,kidney: 1.8;liver: 2.7,lymph node: 0.5,Cell line enhanced,,BEWO: 1.3;CACO-2: 2.4;MCF7: 1.6;SiHa: 3.5
38,CHST13,C4ST3,ENSG00000180767,Carbohydrate sulfotransferase 13,3,126524283-126543291,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,liver: 5.9;testis: 6.3,spleen: 2.9,Group enriched,6.0,CACO-2: 13.9;Hep G2: 20.6;NB-4: 12.8;THP-1: 7.9
39,CRHBP,"CRF-BP, CRFBP",ENSG00000145708,Corticotropin releasing hormone binding protein,5,76952713-76981158,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA046120,Approved,,,,,Tissue enhanced,Tissue enhanced,,liver: 69.9;spleen: 42.2,kidney: 30.2,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 3.2;BJ hTERT+ SV40 Large T+ RasG12V: 3.3;HBF TERT88: 6.0;U-698: 4.8;U-87 MG: 3.6;WM-115: 3.2
40,CUX2,"CDP2, CUTL2, KIAA0293",ENSG00000111249,Cut like homeobox 2,12,111034024-111350554,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 12.2;liver: 9.6;prostate: 18.0,thyroid gland: 6.8,Cell line enhanced,,HBEC3-KT: 4.6;SCLC-21H: 7.5;SH-SY5Y: 14.5
41,CXCL2,"CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, SCYB2",ENSG00000081041,C-X-C motif chemokine ligand 2,4,74097035-74099293,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:2.07e-6 (unfavourable), Breast cancer:5.93e-5 (favourable), Cervical cancer:1.41e-4 (unfavourable)",Expressed in all,Tissue enhanced,,liver: 110.2,lung: 95.2,Cell line enhanced,,BJ hTERT+: 38.3;HHSteC: 26.8;hTCEpi: 24.9;hTEC/SVTERT24-B: 24.7;hTERT-HME1: 25.6;U-87 MG: 27.5
42,CYP27A1,"CP27, CTX, CYP27",ENSG00000135929,Cytochrome P450 family 27 subfamily A member 1,2,218781749-218815293,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA059155,Enhanced,,Enhanced,Mitochondria,"Liver cancer:8.62e-6 (favourable), Breast cancer:1.05e-4 (favourable)",Expressed in all,Tissue enhanced,,liver: 279.5,lung: 98.4,Cell line enhanced,,Hep G2: 187.0;RPTEC TERT1: 50.8;SK-MEL-30: 86.7;WM-115: 42.3
43,CYP2C19,"CPCJ, CYP2C, P450IIC19",ENSG00000165841,Cytochrome P450 family 2 subfamily C member 19,10,94762624-94853260,"Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA015066,Supported,,,,,Not detected,Tissue enhanced,,duodenum: 48.3;liver: 125.6,small intestine: 20.7,Not detected,,
44,CYP2J2,,ENSG00000134716,Cytochrome P450 family 2 subfamily J member 2,1,59893308-59926790,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:5.54e-7 (unfavourable),Mixed,Tissue enhanced,,liver: 74.4;small intestine: 92.3,heart muscle: 57.5,Cell line enhanced,,RT4: 48.3;SK-BR-3: 12.0
45,CYP39A1,,ENSG00000146233,Cytochrome P450 family 39 subfamily A member 1,6,46549580-46652830,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:1.86e-4 (favourable),Tissue enhanced,Tissue enhanced,,liver: 56.8,epididymis: 28.9,Cell line enhanced,,hTCEpi: 11.0;SiHa: 9.9;U-698: 7.7
46,CYP3A5,"CP35, P450PCN3, PCN3",ENSG00000106258,Cytochrome P450 family 3 subfamily A member 5,7,99648194-99679998,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA072245,,,Uncertain,Cytosol,Liver cancer:3.72e-5 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 114.8;liver: 93.2;small intestine: 187.6,stomach: 77.7,Cell line enhanced,,A549: 2.5;CACO-2: 7.9;CAPAN-2: 5.7;Hep G2: 5.0
47,CYP3A7-CYP3A51P,,ENSG00000282301,CYP3A7-CYP3A51P readthrough,7,99684957-99735102,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA072245,,,Uncertain,Cytosol,,,Tissue enhanced,,liver: 7.4,gallbladder: 1.9,Not detected,,
48,CYP4F11,,ENSG00000171903,Cytochrome P450 family 4 subfamily F member 11,19,15912367-15934867,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA017265, CAB033648, HPA058960",Enhanced,,,,"Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable)",Mixed,Tissue enhanced,,gallbladder: 29.5;liver: 32.7;small intestine: 26.3,epididymis: 20.0,Cell line enhanced,,A-431: 11.4;CAPAN-2: 44.2;EFO-21: 17.4;Hep G2: 17.0;RT4: 12.1
49,CYP4F3,"CYP4F, LTB4H",ENSG00000186529,Cytochrome P450 family 4 subfamily F member 3,19,15640897-15662825,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA058960,Approved,,,,,Tissue enhanced,Tissue enhanced,,bone marrow: 53.1;liver: 98.0,kidney: 29.4,Group enriched,7.0,A549: 6.6;CAPAN-2: 28.8;HaCaT: 13.3;Hep G2: 12.4
50,DEPDC7,,ENSG00000121690,DEP domain containing 7,11,33015864-33033582,Predicted intracellular proteins,Evidence at protein level,HPA015800,,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Liver cancer:7.26e-4 (favourable),Mixed,Tissue enhanced,,liver: 37.6;testis: 50.7,small intestine: 31.2,Cell line enhanced,,LHCN-M2: 44.3;RH-30: 38.6;SiHa: 39.2
51,DGAT2,,ENSG00000062282,Diacylglycerol O-acyltransferase 2,11,75759512-75801535,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Endometrial cancer:2.84e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,adipose tissue: 493.2;liver: 170.9,skin: 116.1,Cell line enhanced,,ASC diff: 55.2;HDLM-2: 57.8
52,DNAJC25,bA16L21.2.1,ENSG00000059769,DnaJ heat shock protein family (Hsp40) member C25,9,111631352-111654351,Predicted membrane proteins,Evidence at protein level,HPA019122,Approved,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:3.73e-4 (favourable),Expressed in all,Tissue enhanced,,liver: 16.7,parathyroid gland: 7.9,Mixed,,
53,DNASE1L3,"DNAS1L3, LSD",ENSG00000163687,Deoxyribonuclease 1 like 3,3,58192257-58214697,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA019955,Approved,,,,"Renal cancer:1.06e-7 (favourable), Liver cancer:1.20e-6 (favourable)",Mixed,Tissue enhanced,,liver: 136.7;spleen: 316.5,tonsil: 51.2,Cell line enhanced,,BEWO: 1.8;RPMI-8226: 1.4
54,ECHDC2,FLJ10948,ENSG00000121310,Enoyl-CoA hydratase domain containing 2,1,52895910-52927212,Predicted intracellular proteins,Evidence at protein level,"HPA026731, HPA026768",Enhanced,,Approved,Mitochondria,"Urothelial cancer:2.70e-4 (favourable), Head and neck cancer:6.65e-4 (favourable)",Expressed in all,Tissue enhanced,,liver: 47.8,kidney: 26.3,Cell line enhanced,,BEWO: 15.6;HHSteC: 9.5
55,ELFN1,PPP1R28,ENSG00000225968,Extracellular leucine rich repeat and fibronectin type III domain containing 1,7,1688119-1747954,Predicted membrane proteins,Evidence at protein level,HPA066382,,,Approved,Nucleoplasm<br>Cell Junctions,Liver cancer:9.68e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 3.5;liver: 3.7,endometrium: 1.7,Cell line enhanced,,REH: 28.4;U-138 MG: 18.3;U-2 OS: 28.4;U-2197: 29.8
56,ELOVL2,Ssc2,ENSG00000197977,ELOVL fatty acid elongase 2,6,10980759-11044314,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Breast cancer:6.73e-5 (favourable),Group enriched,Tissue enhanced,,liver: 27.6;parathyroid gland: 36.7;placenta: 50.2,cerebral cortex: 22.8,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 29.1;HBF TERT88: 28.0;RH-30: 30.7
57,ENTPD5,"CD39L4, NTPDase-5, PCPH",ENSG00000187097,Ectonucleoside triphosphate diphosphohydrolase 5,14,73958010-74019399,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA002927,Enhanced,,Approved,Cytosol,Renal cancer:3.95e-5 (favourable),Expressed in all,Tissue enhanced,,liver: 130.4,rectum: 111.3,Expressed in all,,
58,EPO,EP,ENSG00000130427,Erythropoietin,7,100720800-100723700,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,CAB010336,Supported,,,,"Renal cancer:2.18e-6 (unfavourable), Liver cancer:5.67e-5 (unfavourable)",Group enriched,Tissue enhanced,,"cervix, uterine: 2.0;endometrium: 1.7;liver: 1.7",prostate: 1.1,Group enriched,6.0,BEWO: 2.0;Hep G2: 5.5
59,ETNK2,"EKI2, FLJ10761",ENSG00000143845,Ethanolamine kinase 2,1,204131062-204152003,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA057167,Enhanced,,,,"Glioma:3.43e-4 (unfavourable), Renal cancer:6.50e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 110.6;liver: 120.7;testis: 143.1,ovary: 43.4,Mixed,,
60,EVA1A,"FAM176A, FLJ13391, TMEM166",ENSG00000115363,"Eva-1 homolog A, regulator of programmed cell death",2,75469302-75569722,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008055,Approved,,Supported,Vesicles<br>Plasma membrane,"Ovarian cancer:5.67e-4 (favourable), Renal cancer:5.80e-4 (favourable)",Mixed,Tissue enhanced,,liver: 98.9,lung: 31.1,Cell line enhanced,,U-138 MG: 109.1
61,F10,,ENSG00000126218,Coagulation factor X,13,113122814-113149529,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Pancreatic cancer:1.82e-5 (favourable), Renal cancer:5.14e-5 (unfavourable)",Tissue enriched,Tissue enhanced,,liver: 67.5,"cervix, uterine: 51.6",Cell line enhanced,,BJ: 12.5;Hep G2: 40.8;SH-SY5Y: 30.0
62,F11,FXI,ENSG00000088926,Coagulation factor XI,4,186265945-186288806,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA039808,,,Approved,Vesicles,Liver cancer:3.29e-5 (favourable),Tissue enriched,Tissue enhanced,,liver: 180.1,kidney: 44.7,Cell line enriched,8.0,Hep G2: 6.0
63,FBP1,FBP,ENSG00000165140,Fructose-bisphosphatase 1,9,94603133-94640249,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA005857, HPA012513, CAB033869",Enhanced,,Uncertain,Mitochondria,"Renal cancer:6.86e-7 (favourable), Urothelial cancer:1.64e-5 (favourable), Liver cancer:1.79e-4 (favourable), Endometrial cancer:5.16e-4 (favourable)",Expressed in all,Tissue enhanced,,liver: 443.9,duodenum: 329.6,Cell line enhanced,,HaCaT: 66.7;MCF7: 184.8;RT4: 124.5;U-698: 78.4
64,FMO4,FMO2,ENSG00000076258,Flavin containing monooxygenase 4,1,171314208-171342084,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA049100,Uncertain,,,,"Liver cancer:1.09e-4 (favourable), Renal cancer:6.96e-4 (favourable), Lung cancer:7.45e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 48.2;liver: 30.1,parathyroid gland: 10.9,Cell line enhanced,,EFO-21: 5.2
65,FMO5,,ENSG00000131781,Flavin containing monooxygenase 5,1,147175351-147243050,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012373,Enhanced,,Supported,Endoplasmic reticulum<br>Cytosol,Renal cancer:1.34e-6 (favourable),Tissue enriched,Tissue enhanced,,liver: 324.7,small intestine: 75.4,Cell line enhanced,,Hep G2: 26.6;HMC-1: 7.7;THP-1: 6.7
66,FUOM,"C10orf125, FLJ26016, FucM, FucU",ENSG00000148803,Fucose mutarotase,10,133355154-133358035,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039207,Uncertain,,,,,Expressed in all,Tissue enhanced,,liver: 74.9,duodenum: 50.9,Mixed,,
67,G6PC,"G6PT, GSD1a",ENSG00000131482,Glucose-6-phosphatase catalytic subunit,17,42900797-42913369,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA052324,Enhanced,,,,"Renal cancer:3.79e-5 (favourable), Liver cancer:5.42e-5 (favourable)",Tissue enriched,Tissue enhanced,,kidney: 89.1;liver: 147.3,small intestine: 33.2,Not detected,,
68,GAS2,,ENSG00000148935,Growth arrest specific 2,11,22625642-22813055,Predicted intracellular proteins,Evidence at protein level,HPA058904,Enhanced,,Approved,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol,Renal cancer:6.13e-4 (favourable),Tissue enhanced,Tissue enhanced,,liver: 20.4,kidney: 5.5,Group enriched,11.0,Hep G2: 29.5;Karpas-707: 61.6;SCLC-21H: 29.3;U-266/84: 21.3
69,GJB1,"CMTX, CMTX1, CX32",ENSG00000169562,Gap junction protein beta 1,X,71215194-71225516,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,CAB012994,Uncertain,,,,Renal cancer:2.85e-6 (favourable),Tissue enhanced,Tissue enhanced,,liver: 159.4,gallbladder: 59.2,Group enriched,6.0,Hep G2: 94.2;SK-MEL-30: 123.7
70,GLDC,"GCSP, NKH",ENSG00000178445,Glycine decarboxylase,9,6532464-6645783,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002318, HPA052887",Enhanced,,Supported,Nucleus<br>Mitochondria,"Endometrial cancer:5.24e-5 (unfavourable), Renal cancer:3.50e-4 (favourable)",Tissue enhanced,Tissue enhanced,,kidney: 30.3;liver: 19.9;placenta: 20.1,cerebral cortex: 10.6,Cell line enhanced,,BEWO: 206.9;RPTEC TERT1: 67.4
71,GLTPD2,,ENSG00000182327,Glycolipid transfer protein domain containing 2,17,4788959-4790390,Predicted secreted proteins,Evidence at protein level,"HPA058295, HPA065267",Uncertain,,Approved,Vesicles,,Tissue enriched,Tissue enhanced,,duodenum: 11.0;kidney: 12.8;liver: 13.8,small intestine: 7.2,Cell line enhanced,,CACO-2: 8.6;Hep G2: 9.4
72,GLYCTK,"HBEBP2, HBEBP4",ENSG00000168237,Glycerate kinase,3,52287089-52293476,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA006913,Approved,,Approved,Golgi apparatus<br>Cytosol<br>Rods & Rings,Head and neck cancer:1.64e-4 (favourable),Tissue enriched,Tissue enhanced,,duodenum: 38.3;liver: 60.6,small intestine: 31.8,Expressed in all,,
73,GOLT1A,"CGI-141, FLJ42654, GOT1, MGC62027, YMR292W",ENSG00000174567,Golgi transport 1A,1,204198160-204214092,Predicted membrane proteins,Evidence at protein level,,,,,,"Renal cancer:6.35e-5 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Glioma:5.49e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,duodenum: 40.3;liver: 79.1;small intestine: 42.3,parathyroid gland: 28.1,Cell line enhanced,,CACO-2: 12.3;CAPAN-2: 14.9;Hep G2: 14.6;MCF7: 27.7;RT4: 18.6;SK-BR-3: 17.2
74,GPLD1,,ENSG00000112293,Glycosylphosphatidylinositol specific phospholipase D1,6,24424565-24495205,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB008625, HPA012500",Uncertain,,,,Liver cancer:1.12e-4 (favourable),Tissue enriched,Tissue enhanced,,liver: 23.6,skin: 9.0,Cell line enhanced,,Daudi: 5.7;U-698: 5.6
75,GRB14,,ENSG00000115290,Growth factor receptor bound protein 14,2,164492812-164621848,Predicted intracellular proteins,Evidence at protein level,"CAB022294, HPA035052, HPA035053",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,epididymis: 6.1;kidney: 6.2;liver: 6.6,testis: 4.3,Cell line enhanced,,HUVEC TERT2: 7.9;RPTEC TERT1: 5.9;TIME: 9.9
76,GSTA1,,ENSG00000243955,Glutathione S-transferase alpha 1,6,52791664-52803910,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004342, HPA048934, HPA053817",Supported,,Supported,Cytosol,"Renal cancer:3.71e-4 (unfavourable), Lung cancer:8.66e-4 (favourable)",Group enriched,Tissue enhanced,,adrenal gland: 1136.4;kidney: 1310.9;liver: 1757.6,small intestine: 1002.9,Cell line enriched,11.0,Hep G2: 245.8
77,GSTM1,"GST1, H-B, MU",ENSG00000134184,Glutathione S-transferase mu 1,1,109687814-109709039,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB022669, CAB047357, HPA048652, HPA055972, HPA055973",Approved,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,liver: 317.1,parathyroid gland: 233.1,Cell line enhanced,,HEL: 78.7;HeLa: 68.9;HHSteC: 66.1;hTEC/SVTERT24-B: 72.9;MOLT-4: 92.2
78,HAAO,,ENSG00000162882,"3-hydroxyanthranilate 3,4-dioxygenase",2,42767089-42792593,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036394, HPA042024",Enhanced,,,,Liver cancer:5.77e-4 (favourable),Group enriched,Tissue enhanced,,liver: 152.2,small intestine: 45.5,Cell line enhanced,,CACO-2: 11.2;Hep G2: 32.9;REH: 9.2
79,HGD,"AKU, HGO",ENSG00000113924,"Homogentisate 1,2-dioxygenase",3,120628173-120682571,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA047374, HPA052359",Enhanced,,Supported,Golgi apparatus,Endometrial cancer:1.78e-4 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 175.8;liver: 324.3,gallbladder: 87.1,Group enriched,10.0,CACO-2: 38.8;EFO-21: 75.8;Hep G2: 110.3;RPTEC TERT1: 153.1
80,HMGCS2,,ENSG00000134240,3-hydroxy-3-methylglutaryl-CoA synthase 2,1,119747996-119768905,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA027423, HPA027442, CAB032906",Enhanced,,Supported,Mitochondria,"Liver cancer:2.43e-7 (favourable), Renal cancer:3.43e-5 (favourable), Ovarian cancer:2.17e-4 (favourable)",Tissue enhanced,Tissue enhanced,,liver: 1270.5,colon: 363.4,Cell line enriched,15.0,RT4: 161.6
81,HOGA1,"C10orf65, DHDPS2, DHDPSL, FLJ37472, NPL2",ENSG00000241935,4-hydroxy-2-oxoglutarate aldolase 1,10,97584323-97612802,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA039466,Approved,,,,Renal cancer:9.08e-4 (favourable),Group enriched,Tissue enhanced,,kidney: 53.4;liver: 20.7,heart muscle: 8.5,Cell line enhanced,,EFO-21: 9.0;Hep G2: 17.6;RPTEC TERT1: 23.2
82,HPN,TMPRSS1,ENSG00000105707,Hepsin,19,35040506-35066571,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006804,Approved,,,,Renal cancer:5.45e-5 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 99.7;liver: 155.4,prostate: 31.6,Group enriched,7.0,EFO-21: 29.1;Hep G2: 31.2;T-47d: 20.3
83,HS3ST3B1,"30ST3B1, 3OST3B1",ENSG00000125430,Heparan sulfate-glucosamine 3-sulfotransferase 3B1,17,14301083-14349404,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA064126,,,Approved,Vesicles,,Mixed,Tissue enhanced,,liver: 14.7,lymph node: 7.1,Cell line enhanced,,AF22: 20.5;BEWO: 14.3;HSkMC: 14.6;U-251 MG: 16.3
84,HYAL1,"FUS2, HYAL-1, LUCA1, NAT6",ENSG00000114378,Hyaluronoglucosaminidase 1,3,50299889-50312381,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA002112,Uncertain,,,,"Renal cancer:1.56e-11 (favourable), Colorectal cancer:2.07e-4 (favourable)",Expressed in all,Tissue enhanced,,liver: 71.1;spleen: 69.3,kidney: 43.5,Cell line enhanced,,Hep G2: 66.6;SK-BR-3: 20.5
85,IL1RAP,"C3orf13, IL-1RAcP, IL1R3",ENSG00000196083,Interleukin 1 receptor accessory protein,3,190514051-190659750,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035293,Uncertain,,Approved,Vesicles<br>Cytosol,"Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,liver: 113.0;placenta: 53.7,gallbladder: 19.8,Cell line enhanced,,SK-MEL-30: 193.6
86,IL27,"IL-27, IL-27A, IL27A, IL27p28, IL30, MGC71873, p28",ENSG00000197272,Interleukin 27,16,28499362-28512051,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB024722,Approved,,,,Liver cancer:1.30e-4 (favourable),Tissue enriched,Tissue enhanced,,liver: 8.0,appendix: 1.6,Cell line enriched,15.0,BEWO: 17.2
87,KDM8,"FLJ13798, JMJD5",ENSG00000155666,Lysine demethylase 8,16,27203495-27221768,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA026545,Uncertain,,Approved,Nucleoplasm<br>Cytosol,Pancreatic cancer:1.75e-4 (favourable),Expressed in all,Tissue enhanced,,liver: 24.2,small intestine: 13.8,Mixed,,
88,KLB,,ENSG00000134962,Klotho beta,4,39406853-39451536,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA021136,Uncertain,,,,,Tissue enriched,Tissue enhanced,,adipose tissue: 20.6;liver: 9.1,testis: 5.0,Group enriched,19.0,ASC diff: 4.5;Hep G2: 17.2
89,KMO,,ENSG00000117009,Kynurenine 3-monooxygenase,1,241532134-241595642,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA031115, HPA056942",Enhanced,,,,Renal cancer:6.49e-8 (unfavourable),Mixed,Tissue enhanced,,kidney: 32.3;liver: 47.7,spleen: 10.8,Cell line enhanced,,RPMI-8226: 6.1;RPTEC TERT1: 16.3;SK-BR-3: 8.4;U-698: 6.4
90,LGSN,"GLULD1, LGS",ENSG00000146166,"Lengsin, lens protein with glutamine synthetase domain",6,63275951-63319977,Predicted intracellular proteins,Evidence at protein level,"HPA030957, HPA039983",Enhanced,,Approved,Nucleoplasm<br>Vesicles,,Tissue enhanced,Tissue enhanced,,kidney: 2.8;liver: 2.4;placenta: 1.8,testis: 0.7,Cell line enhanced,,A549: 5.5;BEWO: 3.0;CACO-2: 1.6;HeLa: 1.5
91,LIME1,"dJ583P15.4, FLJ20406, LIME",ENSG00000203896,Lck interacting transmembrane adaptor 1,20,63736283-63739103,Predicted secreted proteins,Evidence at protein level,CAB015363,Approved,,,,"Urothelial cancer:6.92e-6 (favourable), Renal cancer:5.04e-5 (unfavourable)",Expressed in all,Tissue enhanced,,liver: 19.6;stomach: 17.6,kidney: 15.2,Cell line enhanced,,MOLT-4: 31.1;RPMI-8226: 97.2;U-266/70: 55.2
92,METTL7B,"ALDI, MGC17301",ENSG00000170439,Methyltransferase like 7B,12,55681546-55684611,Predicted secreted proteins,Evidence at protein level,HPA038644,Enhanced,,Supported,Vesicles<br>Microtubules,"Thyroid cancer:2.37e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable)",Mixed,Tissue enhanced,,epididymis: 137.1;liver: 122.2,small intestine: 52.1,Cell line enhanced,,CAPAN-2: 42.8;EFO-21: 33.6;LHCN-M2: 33.5;U-87 MG: 35.3
93,MLIP,"C6orf142, CIP, MGC18257",ENSG00000146147,Muscular LMNA interacting protein,6,53929982-54266280,Predicted intracellular proteins,Evidence at protein level,"HPA029252, HPA046654",Approved,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,heart muscle: 112.5;liver: 67.0;skeletal muscle: 45.7,skin: 20.6,Group enriched,7.0,HUVEC TERT2: 16.4;SK-MEL-30: 14.9
94,MST1,"D3F15S2, DNF15S2, HGFL, MSP, NF15S2",ENSG00000173531,Macrophage stimulating 1,3,49683947-49689501,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA024036,Uncertain,,,,Pancreatic cancer:7.14e-4 (favourable),Tissue enriched,Tissue enhanced,,liver: 144.2,duodenum: 51.1,Cell line enhanced,,Hep G2: 57.1;U-266/70: 16.6
95,MT1B,"MT1, MT1Q",ENSG00000169688,Metallothionein 1B,16,56651899-56653204,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,duodenum: 1.3;liver: 3.2,appendix: 0.5,Not detected,,
96,NNMT,,ENSG00000166741,Nicotinamide N-methyltransferase,11,114257787-114313285,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA059180,Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,"Renal cancer:1.02e-6 (unfavourable), Stomach cancer:1.75e-4 (unfavourable), Head and neck cancer:2.07e-4 (unfavourable)",Expressed in all,Tissue enhanced,,liver: 197.2,adipose tissue: 107.8,Cell line enhanced,,HSkMC: 300.0;RPTEC TERT1: 491.7
97,NPW,PPL8,ENSG00000183971,Neuropeptide W,16,2009926-2020755,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA064874,Approved,,,,,Mixed,Tissue enhanced,,liver: 5.2;stomach: 2.9,epididymis: 1.7,Cell line enhanced,,NB-4: 29.9;RPMI-8226: 57.2;SCLC-21H: 161.6
98,NR0B2,SHP,ENSG00000131910,Nuclear receptor subfamily 0 group B member 2,1,26911489-26913966,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,duodenum: 78.6;liver: 48.8,small intestine: 28.9,Cell line enriched,19.0,Hep G2: 53.5
99,NR1H4,"FXR, HRR-1, HRR1, RIP14",ENSG00000012504,Nuclear receptor subfamily 1 group H member 4,12,100473708-100564413,"Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters",Evidence at protein level,HPA047699,,,Approved,Nucleoplasm,,Group enriched,Tissue enhanced,,liver: 66.6;small intestine: 44.4,kidney: 29.9,Group enriched,26.0,Hep G2: 20.2;HHSteC: 14.1;RPTEC TERT1: 34.8
100,OSGIN1,"BDGI, OKL38",ENSG00000140961,Oxidative stress induced growth inhibitor 1,16,83948282-83966332,Predicted intracellular proteins,Evidence at protein level,HPA019239,,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:4.89e-5 (favourable),Tissue enriched,Tissue enhanced,,liver: 57.3,duodenum: 31.3,Cell line enhanced,,A549: 60.9;Hep G2: 69.5;T-47d: 69.3;WM-115: 61.3
101,OXT,"OT, OT-NPI, OXT-NPI",ENSG00000101405,Oxytocin/neurophysin I prepropeptide,20,3071620-3072517,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA071892,Supported,Supported,,,,Tissue enriched,Tissue enhanced,,liver: 2.1;small intestine: 1.1,duodenum: 1.1,Cell line enhanced,,CACO-2: 1.3;HMC-1: 1.0
102,PAH,PH,ENSG00000171759,Phenylalanine hydroxylase,12,102836885-102958410,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028407, HPA031642",Enhanced,,Approved,Endoplasmic reticulum<br>Vesicles,Liver cancer:4.30e-4 (favourable),Tissue enriched,Tissue enhanced,,kidney: 504.6;liver: 722.4,gallbladder: 125.9,Cell line enriched,26.0,Hep G2: 161.3
103,PANK1,"MGC24596, PANK, PANK1a, PANK1b",ENSG00000152782,Pantothenate kinase 1,10,89579497-89645572,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:1.55e-10 (favourable), Liver cancer:1.50e-4 (favourable)",Mixed,Tissue enhanced,,kidney: 46.6;liver: 55.1,duodenum: 20.6,Mixed,,
104,PAQR9,FLJ41938,ENSG00000188582,Progestin and adipoQ receptor family member 9,3,142949164-142963682,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA052798,Uncertain,,,,,Tissue enriched,Tissue enhanced,,heart muscle: 5.6;liver: 6.8;testis: 19.3,bone marrow: 3.4,Cell line enhanced,,A549: 3.0;AF22: 2.0;HEL: 2.1;NTERA-2: 2.5;U-266/70: 4.6;U-266/84: 2.4
105,PCK1,PEPCK-C,ENSG00000124253,Phosphoenolpyruvate carboxykinase 1,20,57561080-57568112,"Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006277, HPA006507, CAB017027",Approved,,,,Renal cancer:1.47e-5 (favourable),Tissue enriched,Tissue enhanced,,kidney: 425.9;liver: 319.7,small intestine: 157.6,Cell line enriched,9.0,ASC diff: 14.0
106,PCSK6,"PACE4, SPC4",ENSG00000140479,Proprotein convertase subtilisin/kexin type 6,15,101297142-101525202,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA004774,Uncertain,,,,"Renal cancer:7.06e-7 (unfavourable), Breast cancer:9.99e-4 (favourable)",Mixed,Tissue enhanced,,liver: 90.3;spleen: 124.6,placenta: 53.9,Cell line enhanced,,BEWO: 57.8;HEK93: 58.5;Hep G2: 39.9
107,PCSK9,"FH3, HCHOLA3, NARC-1",ENSG00000169174,Proprotein convertase subtilisin/kexin type 9,1,55039548-55064852,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Urothelial cancer:2.40e-4 (unfavourable),Mixed,Tissue enhanced,,liver: 6.1;lung: 11.1,colon: 3.4,Cell line enhanced,,A-431: 72.0;HaCaT: 94.8;HeLa: 62.7;RPTEC TERT1: 39.4
108,PKLR,,ENSG00000143627,"Pyruvate kinase, liver and RBC",1,155289839-155301434,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006653, CAB034376, CAB034378",Enhanced,,Approved,Endoplasmic reticulum<br>Golgi apparatus,,Tissue enriched,Tissue enhanced,,kidney: 14.0;liver: 26.4,bone marrow: 7.8,Cell line enriched,16.0,K-562: 72.0
109,PNPLA3,"adiponutrin, ADPN, C22orf20, dJ796I17.1, FLJ22012, iPLA2epsilon",ENSG00000100344,Patatin like phospholipase domain containing 3,22,43923739-43964488,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA058058,Approved,,Approved,Nucleoli<br>Mitochondria<br>Cytosol,,Tissue enhanced,Tissue enhanced,,liver: 16.2,kidney: 4.7,Mixed,,
110,PROS1,PROS,ENSG00000184500,Protein S (alpha),3,93873033-93974066,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007724, HPA023974",Enhanced,,,,"Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable)",Expressed in all,Tissue enhanced,,liver: 177.6,heart muscle: 78.3,Cell line enhanced,,ASC diff: 98.8;SK-MEL-30: 127.4
111,PROX1,,ENSG00000117707,Prospero homeobox 1,1,213983181-214041502,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA000842, HPA001030",,,Supported,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,liver: 45.3,adrenal gland: 13.3,Cell line enhanced,,Hep G2: 21.7;RH-30: 15.7;SH-SY5Y: 83.1
112,RBP5,CRBPIII,ENSG00000139194,Retinol binding protein 5,12,7123684-7128942,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA038723,Enhanced,,Approved,Golgi apparatus<br>Vesicles,"Urothelial cancer:3.68e-4 (favourable), Lung cancer:8.37e-4 (favourable)",Group enriched,Tissue enhanced,,kidney: 455.7;liver: 204.9,spleen: 102.0,Cell line enhanced,,Hep G2: 17.0;K-562: 46.6
113,RELN,"PRO1598, RL",ENSG00000189056,Reelin,7,103471784-103989516,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA046512,,,Approved,Plasma membrane<br>Focal adhesion sites,,Tissue enhanced,Tissue enhanced,,liver: 17.8,cerebral cortex: 7.3,Cell line enhanced,,Hep G2: 43.5;PC-3: 11.6;SCLC-21H: 17.5;SH-SY5Y: 17.2;TIME: 29.6
114,RGN,"RC, SMP30",ENSG00000130988,Regucalcin,X,47078355-47093314,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029102, HPA029103",Enhanced,,Approved,Nucleus,"Renal cancer:5.10e-10 (favourable), Liver cancer:7.55e-4 (favourable)",Tissue enriched,Tissue enhanced,,adrenal gland: 202.7;liver: 196.4,kidney: 57.0,Group enriched,6.0,CACO-2: 17.9;fHDF/TERT166: 5.3;Hep G2: 22.3
115,RIPPLY1,,ENSG00000147223,Ripply transcriptional repressor 1,X,106900063-106903335,Predicted secreted proteins,Evidence at protein level,HPA052284,Uncertain,,,,,Group enriched,Tissue enhanced,,kidney: 2.3;liver: 3.0,seminal vesicle: 1.2,Cell line enriched,11.0,RH-30: 6.3
116,RNASE4,RAB1,ENSG00000258818,Ribonuclease A family member 4,14,20684100-20701215,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Liver cancer:9.62e-5 (favourable),Tissue enhanced,Tissue enhanced,,liver: 232.5,prostate: 117.7,Cell line enhanced,,ASC diff: 59.9;ASC TERT1: 68.7;Hep G2: 89.2;HSkMC: 42.8
117,RND1,"ARHS, Rho6, RHOS",ENSG00000172602,Rho family GTPase 1,12,48857145-48865898,Predicted intracellular proteins,Evidence at protein level,HPA077800,,,Supported,Vesicles<br>Plasma membrane<br>Actin filaments,,Mixed,Tissue enhanced,,cerebral cortex: 39.8;liver: 31.1,gallbladder: 23.6,Cell line enriched,6.0,SK-BR-3: 51.2
118,RP11-407N17.3,,ENSG00000258941,CTAGE family member 5 isoform 8 precursor ,14,39233902-39350423,Predicted membrane proteins,Evidence at protein level,"HPA000387, HPA000922, HPA054066, HPA055459",Uncertain,,Approved,Endoplasmic reticulum,,Not detected,Tissue enhanced,,duodenum: 23.9;liver: 22.8;parathyroid gland: 44.1;small intestine: 29.5,kidney: 19.0,Cell line enhanced,,CAPAN-2: 17.3;EFO-21: 5.5;Hep G2: 8.5;RPTEC TERT1: 7.0
119,RP4-583P15.14,,ENSG00000273047,,20,63738270-63740398,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,kidney: 1.1;liver: 2.4;urinary bladder: 1.3,adipose tissue: 1.0,Cell line enhanced,,Hep G2: 4.0;HHSteC: 1.0;U-698: 1.5
120,SAA1,"PIG4, SAA, TP53I4",ENSG00000173432,Serum amyloid A1,11,18266174-18269977,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:4.57e-12 (unfavourable),Tissue enriched,Tissue enhanced,,adipose tissue: 3976.7;liver: 1183.1,"cervix, uterine: 635.0",Group enriched,5.0,HBEC3-KT: 868.8;HHSteC: 212.1
121,SAA2,,ENSG00000134339,Serum amyloid A2,11,18239223-18248643,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:1.30e-8 (unfavourable),Tissue enriched,Tissue enhanced,,"adipose tissue: 713.3;cervix, uterine: 414.7;liver: 581.2",appendix: 211.6,Cell line enhanced,,A-431: 25.4;EFO-21: 20.0;HaCaT: 23.6;HBEC3-KT: 41.5
122,SAA2-SAA4,,ENSG00000255071,SAA2-SAA4 readthrough,11,18231423-18248635,Predicted membrane proteins,Evidence at transcript level,HPA060139,Uncertain,,,,"Renal cancer:2.92e-8 (unfavourable), Breast cancer:4.56e-4 (favourable), Glioma:9.87e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,"adipose tissue: 27.9;cervix, uterine: 22.6;liver: 15.0",breast: 5.4,Cell line enhanced,,A-431: 2.3;EFO-21: 1.4
123,SARDH,"DMGDHL1, SDH",ENSG00000123453,Sarcosine dehydrogenase,9,133663560-133739955,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA057267, HPA058086",Approved,,Approved,Mitochondria,Glioma:3.50e-4 (unfavourable),Tissue enriched,Tissue enhanced,,epididymis: 59.3;liver: 43.0,kidney: 12.5,Group enriched,5.0,AN3-CA: 16.3;Hep G2: 20.7;LHCN-M2: 9.2;MOLT-4: 18.0;RH-30: 17.5;RPMI-8226: 26.5;SH-SY5Y: 15.4
124,SEC14L2,"C22orf6, KIAA1186, KIAA1658, SPF, TAP, TAP1",ENSG00000100003,SEC14 like lipid binding 2,22,30396857-30425317,Predicted intracellular proteins,Evidence at protein level,HPA064466,Approved,,Supported,Nucleus<br>Cytosol,"Head and neck cancer:7.63e-6 (unfavourable), Breast cancer:3.05e-4 (favourable)",Expressed in all,Tissue enhanced,,epididymis: 104.9;liver: 125.6;prostate: 83.0,breast: 57.3,Cell line enhanced,,HBEC3-KT: 61.6
125,SERPINA4,"KAL, kallistatin, KLST, KST, PI4",ENSG00000100665,Serpin family A member 4,14,94561091-94569913,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA003607,Approved,,,,Endometrial cancer:2.95e-4 (favourable),Group enriched,Tissue enhanced,,gallbladder: 72.6;liver: 242.7,epididymis: 42.8,Group enriched,36.0,CACO-2: 4.7;Hep G2: 16.4
126,SERPINA5,"PAI3, PCI, PLANH3, PROCI",ENSG00000188488,Serpin family A member 5,14,94561442-94593120,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA056919,,,Approved,Mitochondria,Endometrial cancer:7.72e-4 (favourable),Tissue enhanced,Tissue enhanced,,adrenal gland: 514.2;liver: 405.3;testis: 818.8,gallbladder: 250.7,Cell line enriched,10.0,Hep G2: 176.3
127,SERPINF2,"A2AP, AAP, ALPHA-2-PI, API, PLI",ENSG00000167711,Serpin family F member 2,17,1742836-1755268,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001885, CAB024863",Approved,,Uncertain,Nucleoplasm<br>Vesicles,Liver cancer:2.26e-5 (favourable),Tissue enriched,Tissue enhanced,,epididymis: 117.4;liver: 452.5,kidney: 63.3,Cell line enriched,24.0,Hep G2: 99.1
128,SHBG,"ABP, MGC126834, MGC138391, TEBG",ENSG00000129214,Sex hormone binding globulin,17,7613946-7633383,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,liver: 33.0;testis: 13.7,small intestine: 7.4,Cell line enhanced,,ASC diff: 3.0;HSkMC: 3.1
129,SLC25A18,,ENSG00000182902,Solute carrier family 25 member 18,22,17563439-17590994,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 74.5;liver: 25.2,adipose tissue: 13.8,Cell line enhanced,,BEWO: 8.2
130,SLC30A10,"DKFZp547M236, ZnT-10, ZNT8, ZRC1",ENSG00000196660,Solute carrier family 30 member 10,1,219685427-219958647,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA064547,Enhanced,,,,,Tissue enriched,Tissue enhanced,,duodenum: 2.1;liver: 2.3,testis: 1.2,Cell line enhanced,,HEK93: 1.2
131,SLC51A,OSTalpha,ENSG00000163959,Solute carrier family 51 alpha subunit,3,196211487-196243178,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA039123,Enhanced,,,,Liver cancer:7.54e-4 (favourable),Tissue enriched,Tissue enhanced,,duodenum: 29.3;liver: 35.1;small intestine: 71.3,colon: 9.9,Cell line enhanced,,REH: 3.4
132,SLC6A12,BGT-1,ENSG00000111181,Solute carrier family 6 member 12,12,190077-214570,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA034973,Approved,,Approved,Vesicles,"Renal cancer:2.70e-6 (favourable), Endometrial cancer:1.59e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,kidney: 29.5;liver: 43.6,cerebral cortex: 14.8,Group enriched,10.0,Hep G2: 4.9;RPTEC TERT1: 10.5
133,SPDYC,Ringo2,ENSG00000204710,Speedy/RINGO cell cycle regulator family member C,11,65170154-65173244,Predicted intracellular proteins,Evidence at protein level,HPA039891,Uncertain,,,,Breast cancer:1.20e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,liver: 1.4;testis: 1.5,epididymis: 0.4,Cell line enhanced,,BEWO: 6.0;HEL: 6.3;K-562: 15.4
134,SULT2A1,"DHEA-ST, STD",ENSG00000105398,Sulfotransferase family 2A member 1,19,47870466-47886397,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB018755, HPA041487, HPA063633",Enhanced,,Supported,Cytosol,,Tissue enriched,Tissue enhanced,,adrenal gland: 189.9;liver: 514.2,small intestine: 91.1,Group enriched,30.0,Hep G2: 25.8;RT4: 20.3
135,THPO,"MGDF, MPLLG, TPO",ENSG00000090534,Thrombopoietin,3,184371935-184378144,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:2.48e-6 (unfavourable),Tissue enriched,Tissue enhanced,,liver: 8.9,testis: 3.9,Cell line enhanced,,CACO-2: 4.9;Hep G2: 10.6;K-562: 2.5;RPMI-8226: 2.8
136,THRSP,"Lpgp, LPGP1, S14, SPOT14, THRP",ENSG00000151365,Thyroid hormone responsive,11,78063861-78068351,Predicted intracellular proteins,Evidence at protein level,HPA040642,Approved,,Approved,Nucleoplasm,"Renal cancer:1.16e-4 (unfavourable), Thyroid cancer:3.28e-4 (favourable)",Tissue enhanced,Tissue enhanced,,adipose tissue: 231.2;liver: 182.9,breast: 43.6,Cell line enriched,12.0,ASC diff: 52.2
137,TMEM56,FLJ31842,ENSG00000152078,Transmembrane protein 56,1,95117338-95197607,Predicted membrane proteins,Evidence at protein level,HPA046762,Uncertain,,Approved,Nuclear speckles,,Tissue enhanced,Tissue enhanced,,liver: 66.1,heart muscle: 16.7,Cell line enhanced,,RH-30: 34.4
138,TMEM82,,ENSG00000162460,Transmembrane protein 82,1,15742422-15747982,Predicted membrane proteins,Evidence at protein level,HPA060282,Uncertain,,Uncertain,Nucleoplasm<br>Cytosol,Renal cancer:3.80e-7 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 23.0;liver: 9.0;small intestine: 19.4,kidney: 7.6,Cell line enriched,5.0,CACO-2: 2.6
139,TRIM55,"MURF-2, RNF29",ENSG00000147573,Tripartite motif containing 55,8,66126896-66175487,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038793, HPA053691",Approved,,Approved,Golgi apparatus<br>Cytosol,,Group enriched,Tissue enhanced,,heart muscle: 40.0;liver: 19.7,testis: 13.2,Cell line enriched,17.0,LHCN-M2: 356.6
140,TTC36,HBP21,ENSG00000172425,Tetratricopeptide repeat domain 36,11,118527472-118531197,Predicted intracellular proteins,Evidence at protein level,HPA038731,Enhanced,,Uncertain,Nucleoplasm,Liver cancer:1.81e-5 (favourable),Group enriched,Tissue enhanced,,liver: 64.4,epididymis: 15.5,Cell line enhanced,,SK-BR-3: 5.3
141,UGT3A1,FLJ34658,ENSG00000145626,UDP glycosyltransferase family 3 member A1,5,35951010-36001028,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA047697, HPA056290",Uncertain,,Approved,Vesicles<br>Cytosol,,Group enriched,Tissue enhanced,,kidney: 53.4;liver: 29.2,duodenum: 9.5,Cell line enriched,51.0,RH-30: 26.5
142,UNC93A,"dJ366N23.1, dJ366N23.2",ENSG00000112494,Unc-93 homolog A (C. elegans),6,167271169-167316019,Predicted membrane proteins,Evidence at protein level,HPA035729,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 9.7;liver: 7.1;skin: 17.8,esophagus: 5.6,Group enriched,9.0,CACO-2: 6.1;Hep G2: 2.1;SCLC-21H: 3.7
143,USH2A,"RP39, USH2",ENSG00000042781,Usherin,1,215622894-216423396,"Disease related genes, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,liver: 3.6;testis: 1.0,epididymis: 0.7,Not detected,,
144,VNN3,HSA238982,ENSG00000093134,Vanin 3,6,132722787-132734765,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,bone marrow: 35.3;liver: 15.2,spleen: 9.5,Not detected,,
145,XDH,"XO, XOR",ENSG00000158125,Xanthine dehydrogenase,2,31334321-31414715,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA062641, HPA069323",Supported,,Supported,Nucleus,Urothelial cancer:8.73e-6 (favourable),Mixed,Tissue enhanced,,breast: 48.3;duodenum: 45.6;liver: 35.9;small intestine: 54.6,colon: 11.2,Cell line enhanced,,HBEC3-KT: 14.4;hTERT-HME1: 23.9
146,XXbac-BPG116M5.17,,ENSG00000244255,,6,31927698-31952048,Predicted secreted proteins,Evidence at protein level,"HPA000951, HPA001817, HPA001832",Approved,,,,,Not detected,Tissue enhanced,,liver: 3.3;lung: 2.9,spleen: 1.2,Not detected,,
147,XYLB,"FLJ10343, FLJ12539",ENSG00000093217,Xylulokinase,3,38346760-38421348,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037863, HPA038415",Uncertain,,Approved,Nuclear speckles,Renal cancer:8.57e-4 (favourable),Mixed,Tissue enhanced,,liver: 15.2,kidney: 9.9,Mixed,,
